Is MREO or CRBP more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% Corbus Pharmaceuticals N/A -87.05% -74.22%

Does the media refer more to MREO or CRBP?

In the previous week, Mereo BioPharma Group had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 1 mentions for Corbus Pharmaceuticals. Mereo BioPharma Group's average media sentiment score of 0.15 beat Corbus Pharmaceuticals' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, MREO or ADAG?

Adagene has higher revenue and earnings than Mereo BioPharma Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group $500K 92.75 -$41.88M -$0.04 N/A Adagene $7.67M 24.84 -$17.61M N/A N/A

Is MREO or ADAG more profitable?

Adagene's return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% Adagene N/A N/A N/A

Does the media refer more to MREO or ADAG?

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 2 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Mereo BioPharma Group's score of 0.15 indicating that Adagene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PLX or MREO?

In the previous week, Protalix BioTherapeutics had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for Protalix BioTherapeutics and 4 mentions for Mereo BioPharma Group. Protalix BioTherapeutics' average media sentiment score of 0.21 beat Mereo BioPharma Group's score of 0.15 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MREO or MDWD?

In the previous week, MediWound had 10 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 14 mentions for MediWound and 4 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.15 beat MediWound's score of 0.06 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MREO or MOLN more profitable?

Molecular Partners' return on equity of -66.62% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% Molecular Partners N/A -66.62% -54.85%

Does the media refer more to MREO or MOLN?

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.64 beat Mereo BioPharma Group's score of 0.15 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mereo BioPharma Group (MREO) Competitors

$0.29 0.00 (-0.99%)

As of 08/21/2026 04:00 PM Eastern

Compare

MREO vs. CRBP, ADAG, PLX, MDWD, and MOLN

Should you buy Mereo BioPharma Group stock or one of its competitors? Mereo BioPharma Group's main competitors and comparable companies include Corbus Pharmaceuticals (CRBP), Adagene (ADAG), Protalix BioTherapeutics (PLX), MediWound (MDWD), and Molecular Partners (MOLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mereo BioPharma Group compare to Corbus Pharmaceuticals?

Mereo BioPharma Group (NASDAQ:MREO) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mereo BioPharma Group has higher revenue and earnings than Corbus Pharmaceuticals. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	92.75	-$41.88M	-$0.04	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

Mereo BioPharma Group currently has a consensus price target of $3.25, suggesting a potential upside of 1,019.15%. Corbus Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 294.99%. Given Mereo BioPharma Group's higher probable upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Mereo BioPharma Group has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, meaning that its share price is 159% more volatile than the broader market.

In the previous week, Mereo BioPharma Group had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 1 mentions for Corbus Pharmaceuticals. Mereo BioPharma Group's average media sentiment score of 0.15 beat Corbus Pharmaceuticals' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mereo BioPharma Group's return on equity of -74.82% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

Summary

Mereo BioPharma Group beats Corbus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Adagene?

Mereo BioPharma Group (NASDAQ:MREO) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mereo BioPharma Group currently has a consensus target price of $3.25, indicating a potential upside of 1,019.15%. Adagene has a consensus target price of $10.00, indicating a potential upside of 148.76%. Given Mereo BioPharma Group's higher probable upside, research analysts clearly believe Mereo BioPharma Group is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Mereo BioPharma Group has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Adagene has higher revenue and earnings than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	92.75	-$41.88M	-$0.04	N/A
Adagene	$7.67M	24.84	-$17.61M	N/A	N/A

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 2 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Mereo BioPharma Group's score of 0.15 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
Adagene	N/A	N/A	N/A

Summary

Adagene beats Mereo BioPharma Group on 9 of the 14 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Protalix BioTherapeutics has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.38	$8.31M	$0.23	10.35
Mereo BioPharma Group	$500K	92.75	-$41.88M	-$0.04	N/A

In the previous week, Protalix BioTherapeutics had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for Protalix BioTherapeutics and 4 mentions for Mereo BioPharma Group. Protalix BioTherapeutics' average media sentiment score of 0.21 beat Mereo BioPharma Group's score of 0.15 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mereo BioPharma Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mereo BioPharma Group has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 404.20%. Mereo BioPharma Group has a consensus price target of $3.25, suggesting a potential upside of 1,019.15%. Given Mereo BioPharma Group's higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protalix BioTherapeutics has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Summary

Protalix BioTherapeutics beats Mereo BioPharma Group on 9 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to MediWound?

Mereo BioPharma Group (NASDAQ:MREO) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Mereo BioPharma Group has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, MediWound has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market.

Mereo BioPharma Group has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
MediWound	-170.10%	-47.24%	-24.27%

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 1,019.15%. MediWound has a consensus price target of $33.00, indicating a potential upside of 149.81%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

MediWound has higher revenue and earnings than Mereo BioPharma Group. MediWound is trading at a lower price-to-earnings ratio than Mereo BioPharma Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	92.75	-$41.88M	-$0.04	N/A
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, MediWound had 10 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 14 mentions for MediWound and 4 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.15 beat MediWound's score of 0.06 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mereo BioPharma Group beats MediWound on 9 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Molecular Partners?

Mereo BioPharma Group (NASDAQ:MREO) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Molecular Partners' return on equity of -66.62% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
Molecular Partners	N/A	-66.62%	-54.85%

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mereo BioPharma Group has higher earnings, but lower revenue than Molecular Partners. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	92.75	-$41.88M	-$0.04	N/A
Molecular Partners	$5.65M	31.45	-$74.41M	-$1.94	N/A

Mereo BioPharma Group has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 1,019.15%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 90.34%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.64 beat Mereo BioPharma Group's score of 0.15 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mereo BioPharma Group beats Molecular Partners on 8 of the 15 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.37M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-7.26	11.62	272.33	24.21
Price / Sales	92.75	1,305.37	613.72	90.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.12	17.38	11.25	6.42
Net Income	-$41.88M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-8.94%	3.29%	2.09%	0.08%
1 Month Performance	-0.21%	8.23%	6.64%	3.88%
1 Year Performance	-82.92%	55.05%	25.02%	16.98%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.4523 of 5 stars	$0.29 -1.0%	$3.25 +1,019.1%	-82.9%	$46.37M	$500K	N/A	40	News Coverage Analyst Forecast Gap Up
CRBP Corbus Pharmaceuticals	2.2216 of 5 stars	$10.21 -2.7%	$41.00 +301.6%	+6.0%	$190.63M	N/A	N/A	40
ADAG Adagene	2.3126 of 5 stars	$3.95 +3.0%	$10.00 +153.5%	+68.2%	$185.04M	$9.29M	N/A	260
PLX Protalix BioTherapeutics	2.7395 of 5 stars	$2.30 +0.2%	$12.00 +422.9%	+43.4%	$184.83M	$80.62M	N/A	200	News Coverage Analyst Revision
MDWD MediWound	3.3031 of 5 stars	$13.62 +1.7%	$33.00 +142.3%	-24.9%	$175.08M	$16.96M	N/A	80	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. CRBP, ADAG, PLX, MDWD, and MOLN

How does Mereo BioPharma Group compare to Corbus Pharmaceuticals?

Summary

How does Mereo BioPharma Group compare to Adagene?

Summary

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Summary

How does Mereo BioPharma Group compare to MediWound?

Summary

How does Mereo BioPharma Group compare to Molecular Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. CRBP, ADAG, PLX, MDWD, and MOLN

How does Mereo BioPharma Group compare to Corbus Pharmaceuticals?

Do insiders and institutionals have more ownership in MREO or CRBP?

Which has higher valuation & earnings, MREO or CRBP?

Do analysts recommend MREO or CRBP?

Which has more risk & volatility, MREO or CRBP?

Does the media refer more to MREO or CRBP?

Is MREO or CRBP more profitable?

Summary

How does Mereo BioPharma Group compare to Adagene?

Do insiders and institutionals believe in MREO or ADAG?

Do analysts recommend MREO or ADAG?

Which has more risk & volatility, MREO or ADAG?

Which has stronger earnings and valuation, MREO or ADAG?

Does the media refer more to MREO or ADAG?

Is MREO or ADAG more profitable?

Summary

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Which has preferable earnings & valuation, PLX or MREO?

Does the media prefer PLX or MREO?

Is PLX or MREO more profitable?

Do analysts rate PLX or MREO?

Do insiders & institutionals hold more shares of PLX or MREO?

Which has more volatility and risk, PLX or MREO?

Summary

How does Mereo BioPharma Group compare to MediWound?

Which has more risk and volatility, MREO or MDWD?

Is MREO or MDWD more profitable?

Do analysts rate MREO or MDWD?

Which has preferable valuation and earnings, MREO or MDWD?

Do institutionals & insiders believe in MREO or MDWD?

Does the media refer more to MREO or MDWD?

Summary

How does Mereo BioPharma Group compare to Molecular Partners?

Is MREO or MOLN more profitable?

Do insiders and institutionals have more ownership in MREO or MOLN?

Which has stronger earnings & valuation, MREO or MOLN?

Which has more risk and volatility, MREO or MOLN?

Do analysts prefer MREO or MOLN?

Does the media refer more to MREO or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools